瑞格列奈药效学研究进展

Progress in the pharmacodynamics of Repaglinide

瑞格列奈作为一种短效胰岛素促泌剂已经广泛应用于临床2型糖尿病患者的血糖控制,但临床研究表明患者间的用药差异性很大,除了与患者的β细胞功能及胰岛素抵抗程度相关外,还需考虑遗传多态性所致药效学差异。本文对目前有关瑞格列奈药效学差异及影响因素的作用机制做一总结,希望有助于了解格列奈类药物的作用机制,为临床用药方案提供依据,减少不良反应发生,从而促进临床合理用药。

Repaglinide is a short-acting,oral,insulin secretagogue used for the treatment of type 2 diabetes mellitus.The inter-individual differences of Repaglinide pharmacodynamics are not only correlation with the degree of impaired β-cell function and insulin resistance,but also correlation with the genetic polymorphism of the patients.The mecha nism of pharmacodynamic differences and its influence factors of Repaglinide have been reviewed in this paper,hope to understand its mechanism of action,in order to provide the basis for clinical medication,reduce the incidence of adverse reactions and promote the rational use of clinical drugs.